APYX · Apyx Medical Corp
$3.03
-0.12 (-3.81%)
At close · Aug 20
Market Cap
$127.64M
Shares
42.12M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.03
Open$3.15
Day$3.03–3.29
52W close$1.90–4.86
Avg vol 30d100K
Short int267K · 0.6% float · 4.7d
Short vol30%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−25%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
38%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−7%
trailing
YTD return
−13%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.63% of float · ▲ +6.1% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
67 holders — near 3-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
63%
expanding
EPS growth
+19%
Y/Y
Free cash flow
$-9.1M
Balance sheet
$3.1M
net debt
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
9.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Total revenue
· year ending December 31, 2026
Initiated
$59M – $60M
prior FY $52.84M
midpoint +12.6% Y/Y
Surgical Aesthetics revenue
· year ending December 31, 2026
Initiated
$54M – $55M
OEM revenue
· year ending December 31, 2026
Initiated
$5M
Prior guidance
period ended
· from the 8-K filed Jan 12, 2026
Total revenue
· fourth quarter ended December 31, 2025
$19M – $19.2M
Surgical Aesthetics revenue
· fourth quarter ended December 31, 2025
$16.6M – $16.8M
OEM revenue
· fourth quarter ended December 31, 2025
$2.4M
Total revenue
· full year ended December 31, 2025
$52.7M – $52.9M
Surgical Aesthetics revenue
· full year ended December 31, 2025
$45.2M – $45.4M
OEM revenue
· full year ended December 31, 2025
$7.5M
Guided vs delivered
· last 3 settled
Total revenue
year ending December 31, 2025
guided $50.5M – $52.5M
$52.84M
Beat +2.6%
Total revenue
12 months ending December 31, 2024
guided $49.7M – $52.9M
$48.1M
Miss −6.2%
Total revenue
full year 2023
guided $53M – $54M
$52.35M
Miss −2.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
38%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.63% of float · ▲ +6.1% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
67 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 38%
Range high $5
vs 200-day avg -21%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -1.03M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA loss non-GAAP | 0.7M | second quarter of 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APYX
this stock
Apyx Medical Corp
|
$127.64M | -13.4% | +9.9% | — | 0.6% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APYX | -0.3% | -20.9% | -7.3% | -26.1% | -13.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +1.6% | -24.2% | -18.5% | -28.2% | -25.3% |